Genome-scale metabolic model of Pichia pastoris with native and humanized glycosylation of recombinant proteins by Irani, Z. A. et al.
Genome-Scale Metabolic Model of Pichia pastoris
With Native and Humanized Glycosylation of
Recombinant Proteins
Zahra Azimzadeh Irani,1 Eduard J. Kerkhoven,2 Seyed Abbas Shojaosadati,1 Jens Nielsen2,3
1Biotechnology Group, Faculty of Chemical Engineering, Tarbiat Modares University,
Tehran, Iran; telephone: þ98 21 82883341; fax: þ98 21 82884931;
e-mail: shoja_sa@modares.ac.ir
2Systems and Synthetic Biology, Department of Biology and Biological Engineering,
Chalmers University of Technology, G€oteborg, Sweden
3Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark,
Hørsholm, Denmark; telephone: þ46 31 772 3804; fax: þ46 31 772 3801;
e-mail: nielsenj@chalmers.se
ABSTRACT: Pichia pastoris is used for commercial production of
human therapeutic proteins, and genome-scale models of P. pastoris
metabolism have been generated in the past to study the
metabolism and associated protein production by this yeast. A
major challenge with clinical usage of recombinant proteins
produced by P. pastoris is the difference in N-glycosylation of
proteins produced by humans and this yeast. However, through
metabolic engineering, a P. pastoris strain capable of producing
humanized N-glycosylated proteins was constructed. The current
genome-scale models of P. pastoris do not address native nor
humanized N-glycosylation, and we therefore developed ihGlyco-
pastoris, an extension to the iLC915 model with both native and
humanized N-glycosylation for recombinant protein production,
but also an estimation of N-glycosylation of P. pastoris native
proteins. This new model gives a better prediction of protein yield,
demonstrates the effect of the different types of N-glycosylation of
protein yield, and can be used to predict potential targets for strain
improvement. The model represents a step towards a more
complete description of protein production in P. pastoris, which is
required for using these models to understand and optimize protein
production processes.
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Introduction
Pichia pastoris has been used for the expression of over 200 different
heterologous proteins (Cregg et al., 2000), including the production
of numerous therapeutic recombinant proteins such as human
serum albumin (Kobayashi et al., 1998), human superoxide
dismutase (rhSOD) (Marx et al., 2009), human erythropoietin
(EPO) (Zhan et al., 1999), and human monoclonal antibody 3H6
Fab fragment (FAB) (Gach et al., 2007). The main reasons for using
P. pastoris as a host for heterologous protein production include the
availability of the alcohol oxidase I gene (AOX1) promoter for
controlled gene expression (Cregg et al., 2000), the ability of
growing to high cell densities in bioreactors (Cereghino, 2000), and
the ability of yeasts to perform eukaryotic post-translational
modiﬁcations such as glycosylation, but also ubiquitination,
sumoylation, and myristoylation.
Many human therapeutic proteins undergo a post-translational
modiﬁcation known as N-glycosylation, which can affect the
protein’s secretion, folding, and bioactivity (Helenius and Aebi,
2001). Over 70% of the therapeutic proteins under preclinical and
clinical development are glycosylated (Chung et al., 2010), and it is
therefore, important to include N-glycosylation in studies of
therapeutic recombinant protein expression.
During N-linked glycosylation, which is conserved across yeast
and other eukaryotes (Gemmill and Trimble, 1999), a 14-saccharide
“core” unit is assembled as a membrane-bound dolichyl
pyrophosphate precursor by enzymes located on both sides of
the endoplasmic reticulum (ER), and this core is subsequently
transferred to targeted asparagine residues of proteins (Gemmill
and Trimble, 1999).
Besides N-linked glycosylation, P. pastoris is also capable of
O-linked glycosylation, where the glycan is attached onto the
hydroxyl groups of serine or threonine residue (Puxbaum et al.,
2015). In human cells, there are different types of O-linked
glycan structures, with separate pathways, and their large
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difference with P. pastoris N-linked glycans has limited
glycoengineering of yeast to reproduce humanized O-glyco-
sylation (Puxbaum et al., 2015). However, the percentage of O-
linked glycosylation in Pichia pastoris is small (Gemmill and
Trimble, 1999) and the biological role of O-linked glycosylation
has not been elucidated, although it seems to play some role in
protein folding quality control and is essential for survival
(Delic et al., 2013).
During N-linked glycosylation, after coupling of the core unit
to the protein, terminal glucose and mannose residues are
removed by ER glucosidases and mannosidases prior to entry of
the glycoprotein into the Golgi (Gemmill and Trimble, 1999). The
difference between yeast and mammalian cells occurs once
the glycoprotein exits the ER and enters the Golgi apparatus
(Hamilton and Gerngross, 2007). In contrast to mammals, yeast
does not further trim the N-glycans in the Golgi, but rather
extends them with additional mannose sugars, to produce hyper-
mannosylated glycans. Recent advances have allowed for the
generation of yeast strains capable of replicating the most
essential glycosylation pathways found in mammals (Hamilton
et al., 2006). Glycoengineering has been accomplished to
eliminate the hyper-mannosylated yeast glycans, and to introduce
the required elements for producing human-like sialylated
complex glycans (Bretthauer, 2003; Chiba and Akeboshi, 2009).
These humanized glycoproteins can be attained using metabolic
engineering of P. pastoris.
One of the tools of metabolic engineering is the use of
computational models that describe the metabolic pathways in
cells and can aid in the identiﬁcation of new targets or strategies
for further metabolic engineering (Kerkhoven et al., 2015). A
metabolic model describing N-glycosylation in P. pastoris has
previously been constructed (Eskitoros et al., 2014), however, this
model only consisted of a subset of the metabolic reaction present
in P. pastoris. Metabolic networks can alternatively be studied in
silico with the help of genome-scale metabolic models (GEMs),
which contain all known metabolic reactions within an organism.
GEMs have become instrumental for system-level understanding
of metabolism and its applications in metabolic engineering
(Kim et al., 2014). Computational algorithms such as constraint-
based ﬂux balance analysis (FBA) can then be applied to
investigate GEMs and these methods have been used to study the
objectives and functions of metabolic networks (Kerkhoven et al.,
2015).
To date, three GEMs for P. pastoris have been reported. The
iPP668 model constructed by Chung et al. (2010), the
PpaMBEL1254 model constructed by Sohn et al. (2010) and
the latest GEM, iLC915 model constructed by Caspeta et al. (2012).
While these models contain various reactions involved in
glycoprotein metabolism, they neither include functional
N-glycosylation of recombinant protein nor include reactions
describing the aforementioned humanized glycosylation.
In this study, we developed a functional GEM that describes
both native P. pastoris N-glycosylation and humanized
N-glycosylation for a number of recombinant proteins. An
average N-glycosylation is assumed such that micro- and
macroheterogeneity do not have to be considered. Additionally,
an estimation of N-glycosylation of P. pastoris native proteins is
included. This model facilitates further investigation of the effect
of N-glycosylation on protein production yields.
Materials and Methods
The iLC915 model (Caspeta et al., 2012) was extended as detailed in
this paper to yield the new model, which we named ihGlycopastoris,
for humanized glycosylation in P. pastoris. This model is provided in
SBML format. Model curation and simulation was performed using
the SBML (Keating et al., 2006) and RAVEN Toolbox (Agren et al.,
2013) for MATLAB (Mathworks Inc., MA). MOSEK (MOSEK ApS,
Denmark) was used to solve linear programming problems. The
model was constrained with relative in and outﬂow ﬂuxes as
mentioned in the Results section. Theoretical yields were
normalized to the uptake rate in Cmol.
N-glycosylation of P. pastoris native proteins was estimated based
on experimental data from Saccharomyces cerevisiae. By proteo-
mics, 645 N-glycosylations were detected in the whole S. cerevisiae
proteome (Chen et al., 2014). The length of all S. cerevisiae protein
sequences in the genome is roughly 3 million amino acids, which
translates to an average N-glycosylation on every 4691st amino
acid. With iLC915 biomass containing 3.2956mmol gDCW1
amino acids, 7.03mmol gDCW1 of native, mannose-rich,
N-glycan was added to the biomass equation.
Results and Discussion
The most recent GEM of P.pastoris, iLC915, has been showed to
provide good predictions of both in vivo growth and antibody-
production yields (Caspeta et al., 2012). This model was selected for
further extension with native and humanized N-glycosylation
pathways. Before any additional pathways were added, however,
additional curation of this model was performed, primarily to
render the model more robust. The curations are detailed in
Supplementary Information 1. After this manual curation of
iLC915, we extended the updated model to incorporate both
P. pastoris native N-glycosylation and humanized N-glycosylation,
where the N-glycan group is modiﬁed to resemble human
N-glycans.
Reconstructing the Dolichol Pathway of Native N-Linked
Glycosylation
P. pastoris native N-glycosylation begins in the ER with a 14-residue
sugar that contains three glucose (Glc), nine mannose (Man), and
two N-acetylglucosamine (GlcNAc) residues (Fig. 1), which are
attached to a dolichol carrier (Samuelson et al., 2005). This core
lipid-linked oligosaccharide, (glucosyl)3(mannosyl)9-(N-acetylglu-
cosaminyl)2-diphosphodolichol is subsequently transferred by an
oligosaccharyltransferase (OST) to asparagine residues in a protein
(Karaoglu et al., 1997). Following transfer to the nascent
polypeptide, forming a glycopeptide, three glucose residues and
one mannose residue are removed to produce Man8GlcNAc2, at
which stage the glycopeptide is transported to the Golgi.
In the Golgi, this Man8GlcNAc2 glycan can be further extended
with additional mannose sugars. The number of mannoses is not
set but is affected by various factors such as expression level, carbon
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source, and site accessibility. This is referred to as micro-
heterogeneity, and in P. pastoris, the number of mannoses ranges
between 8 and 11 (Trimble et al., 1991). In ihGlycopastoris,
microheterogeneity is not taken into account, and a weighted
median of 9 mannoses is used in native N-glycosylation.
The reactions of the dolichol and native N-glycosylation pathways
were added to the iLC915model using a recent model of S. cerevisiae
(Feizi, Marras, Nielsen, manuscript in preparation) as a template,
while the reactions were annotated with P. pastoris genes identiﬁed
using literature data and homology with annotated S. cerevisiae
genes.
The model was further extended by incorporating reactions for
N-glycosylation of P. pastoris’ native proteome. Experimental
determination of N-glycosylation on a proteome scale is
technologically challenging and while such data is currently not
available for P. pastoris, these measurements have been performed
for S. cerevisiae (Chen et al., 2014). We therefore incorporated a
rough estimation of N-glycosylation of the P. pastoris proteins based
on the S. cerevisiae data, as described in Materials and Methods,
without taking micro- and macro-heterogeneity into account.
Addition of Humanized N-Linked Glycosylation
In contrast to yeast, mammals do not extend the Man8GlcNAc2
glycan in the Golgi, but rather trim the existing high mannose
structure in three steps to Man5GlcNAc2 by a-1,2-mannosidase,
followed by the addition of GlcNAc by N-acetylglucosaminyltrans-
ferase I (GnTI). A number of subsequent trimming and extension
reactions lead to the production of a sialylated structure (Fig. 1),
which represents the ﬁnal N-glycosylated protein. P. pastoris strains
have been constructed that allow the construction of these human-
like N-glycans.
Both native and humanized N-glycosylation pathways for
P.pastoris (Fig. 1) were added to the iLC915 model in order to
analyze the effect of these changes on the yeast metabolism, and
we named this extended model ihGlycopastoris. To allow the
investigation of various recombinant proteins, we added the
polymerization reactions of several proteins (Table I), differing in
both size and number of glycosylation sites, and generated native
and humanized glycosylation reactions for each of these proteins.
The model can easily be adapted to facilitate the study of
N-glycosylation of other proteins. A detailed overview and
description of the reactions describing N-glycosylation in
ihGlycopastoris are given in Supplementary Information 2–3.
In comparison with other models of N-glycosylation in P. pastoris
(Barrigon et al., 2015; Eskitoros et al., 2014), our model is in the
context of the whole of P. pastoris metabolism, allows both native
and humanized N-glycosylation of multiple recombinant proteins
and estimates N-glycosylation of the native proteome.
Validation of ihGlycopastoris
The updated model (ihGlycopastoris) was validated for its ability to
predict growth rates. Experimental data on exchanges ﬂuxes were
set as constraints in ihGlycopastoris while biomass production was
set as the objective function, and the resulting growth predictions
were compared to reported experimentally measured growth rate
(Dragosits et al., 2009; Jorda et al., 2014; Jungo et al., 2006, 2007a;
Sola et al., 2004, 2007; Tortajada Serra, 2012; Zhang et al., 2004).
Additional to growth data, the model’s ability to predict
recombinant protein production rates in the reported experimental
conditions were also compared to experimental yields (Dragosits
et al., 2009; Jungo et al., 2007a, 2007b; Sola et al., 2007; Zhang et al.,
2004). For each source, several different operating conditions are
compared, e.g., different temperatures using glucose as the carbon
source to produce FAB (Dragosits et al., 2009); high and low dilution
rates using glycerol/methanol mixtures (Sola et al., 2007); glycerol/
methanol mixture with linear increase of the methanol fraction in
Figure 1. Schematic overview of N-linked glycosylation pathways in P. pastoris.
Both native (left) and glycoengineered humanized glycosylation (right) are shown. On
top is the universal dolichol core complex that is made in the ER, while subsequent
steps take part in the Golgi. Man I: mannosidase I; Man II: mannosidase II; GlcNAcT-I:
N-acetylglucosaminyltransferse I; GlcNAcT-II: N-acetylglucosaminyltransferse II; Gal
T: galactosyltransferase; Sia T: sialyltransferase; ManT: mannosyltransferase.
Table I. Different proteins with different length and glycosylation sites.
Protein
Amino
acids
N-glycosylation
sites Nglycosylation sitesAmino acids
Human serum albumin Redhill
variant (Alb-Redhill)a
609 1 0.0016
Interferon-t (INF-t) 195 1 0.0051
Human Interleukin 4 (hIL4) 153 1 0.0065
Human mast cell Chymase
(rhChymase)
247 2 0.0081
Erythropoietin (EPO) 193 3 0.0155
Prostaglandin H synthases (PGHS) 604 4 0.0066
aWhere normal human serum albumin has noN-glycosylation sites, Albumin-Redhill
is mutated A320T, which generates an N-glycosylation site (Brennan et al., 1990).
Irani et al.: N-Glycosylation in Pichia pastoris 963
Biotechnology and Bioengineering
the feed to produce avidin (Jungo et al., 2007a). Both measured
exchange ﬂuxes and growth rates were used to constraint
ihGlycopastoris, while the objective function was set as the
excretion of the relevant protein. As no data was available on protein
yields on humanized N-glycosylated protein production, only native
N-glycosylated protein production predictions could be compared
to experimental data.
The model predictions for growth were in good agreement
(r2¼0.92) with experimental reported growth (Fig. 2A) and as such,
ihGlycopastoris is validated by more experimental growth data than
the iLC915 model (Caspeta et al., 2012). For a number of
experimental conditions, the model was unable to predict protein
production (Fig. 2B). These cases corresponded to conditions where
the model was also under-predicting the growth rate, from which
leads that there are no capacity to produce recombinant protein. For
the cases where the model allowed for protein production, the
predicted rates were substantially higher than the experimental
rates (Fig. 2B). In these cases, other cellular processes, which are not
taken into account in ihGlycopastoris, limit the recombinant protein
production. These processes can be reduced activation of the
protein expression system, or limitations in the protein secretion
capacity (Hohenblum et al., 2004). In particular, the very high
afﬁnity of avidin to biotin, an essential vitamin, might have
detrimental effects when its production increases (Jungo et al.,
2007c). While the model is unable to capture this level of regulation,
it does provide an upper boundary of protein yield.
The Effect of N-Glycosylation on the Protein Yield
To investigate the effect of different forms of N-glycosylation on
recombinant protein yields, theoretical yields were calculated for a
variety of recombinant proteins undergoing native N-glycosylation,
humanized N-glycosylation, or no N-glycosylation at all, where the
latter represents the theoretical yield when N-glycosylation is not
taken into account. Yields were calculated using FBA by setting the
objective function to the excretion of a particular glycosylated form
of a recombinant protein. From this comparison, it becomes clear
that taking N-glycosylation into account is of importance, as the
theoretical yields of native N-glycosylated protein is substantial
lower than non-glycosylated yields (Fig. 3A), i.e., not taking
N-glycosylation into account results in overestimation of the protein
yield. For Alb-Redhill, this indicates the difference between the
theoretical yield of predominant human serum albumin, which has
no N-glycosylation site, and the Redhill variant, that has an
N-glycosylation site introduced due to an A334Tmutation (Brennan
et al., 1990).
Glycoengineering of P. pastoris to produce humanized glycosy-
lated protein results in a further reduction in theoretical protein
yields (Fig. 3A). This is in contrast to previous computational
modelling that was performed of N-glycosylation in P. pastoris
(Eskitoros et al., 2014), where it was concluded that yields of
humanized N-glycosylated proteins are higher than of native
N-glycosylated proteins. The reduced theoretical yield of humanized
in comparison to native N-glycosylation can be explained by the size
of the N-glycan complex, which contains 70 and 84 carbons in
native and humanized forms respectively. In comparison, the model
of (Eskitoros et al., 2014) produces partially humanized
N-glycosylation, which requires lower amount of carbons.
The reduction in yield due to native and humanized
N-glycosylation is not the same for each different recombinant
protein, for example, the theoretical yield of Alb-Redhill is only
nominally affected by N-glycosylation while the reduction in
theoretical yield in EPO is substantial. These differences are caused
by the size of the recombinant protein and their number of N-
glycosylation sites; smaller proteins and more glycosylation sites
result in a larger reduction in yield (cf. Table I and Fig. 3A).
Assessments of theoretical yields as described above were
performed using glucose as a carbon source. Also, the use of
different carbon sources was investigated by changing the carbon
source while keeping the Cmol uptake rate constant. These
simulations indicated that theoretical protein yields vary depending
on carbon source, while this effect is almost identical for all
Figure 2. Comparison of experimental growth rates and proteins productions with model predicted values. Experimentally measured exchange rates of carbon sources,
oxygen etc. from various sources were used to constrain ihGlycopastoris. (A) Specific growth rates were predicted by setting the biomass growth as objective function. (B) Protein
production rates were predicted by constraining the growth, while setting the protein excretion as objective function. Experimental data for protein production rates were obtained
from: FAB (Dragosits et al., 2009), ROL (Sola et al., 2007), avidin (Jungo et al., 2006, 2007a), INF-t (Zhang et al., 2004).
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recombinant proteins and for the different modes of
N-glycosylation (Fig. 3B). In particular, the theoretical protein
yield is primarily decreased in methanol, due to the increased
oxidative phosphorylation. This is also evidenced by the increased
oxygen requirements (Jungo et al., 2007a) (Fig. 3C), while it has
been described previously that the protein yield on methanol
increases signiﬁcantly when a co-substrate is used (SCalik et al.,
2010; Eskitoros and SCalık, 2014; Jungo et al., 2007a).
Prediction of Potential Targets for Protein Yield
Improvement
ihGlycopastoris was subsequently used to predict potential
ampliﬁcation targets that would increase the protein yield. These
predictions were performed for a large protein with few (one)
N-glycosylation sites (Alb-Redhill) and a small protein with
multiple (three) N-glycosylation sites (EPO). Target identiﬁcation
was performed using Flux Scanning based on Enforced Objective
Function (FSEOF), where the model is constrained with an
experimentally measured carbon uptake rate while the exper-
imentally observed protein yield is stepwise increased to the
theoretical yield (Choi et al., 2010). Simultaneously, the biomass
production, which has been set as objective function, decreases due
to competition for nutrients with the protein production. Potential
targets are those reactions whose ﬂux is systematically increasing at
each iterative increase of protein yield. It is worth to note that while
this strategy may increase the yield of protein, it does not address
the quality and activity of the protein and in particular it might
affect the heterogeneity of N-glycosylation.
FSEOF was performed using both native and humanized
N-glycosylation. Experimental protein production rates were set at
0.064mmol gDCW1 h1 for EPO (Eskitoros and SCalık, 2014) and
0.00169mmol gDCW1 h1 human serum albumin (Maccani et al.,
2014) (used here as a proxy for Alb-Redhill). Given the reported
carbon uptake rates, the theoretical production rates of humanized
N-glycosylated proteins were calculated as 6.1mmol gDCW1 h1
for EPO and 0.84mmol gDCW1 h1 for Alb-Redhill (Supple-
mentary Information 4) representing a 95 and 501 fold-change
increase over the experimental production rates. A large number of
reactions that were identiﬁed as consistently increasing at improved
protein yields, but the majority of these reactions could be
contributed to general amino acid biosynthesis, and these reactions
could have been identiﬁed as targets without the use of
computational models. However, it is re-assuring that the model
captures these targets. When the fate of the carbons entering the
model shifts from biomass production to protein production, the
amino acid requirements increase.
Interestingly, N-glycan metabolism was identiﬁed as a
potential target (Table II), indicating that the increased N-glycan
requirements due to increased recombinant protein production
is not compensated by the decrease in N-glycosylation of
native protein. Also biosynthetic pathways for precursors of
N-glycosylation are suggested targets, such as UDP-GlcNAc and
GDP-Man biosynthesis.
Four targets (GNA1, GFA1, UAP1, and PCM1) are involved in the
biosynthesis of UDP-GlcNAc, where fructose 6-phoshate is derived
from glucose and converted to glucosamine-6-phosphate (GlcN-6P)
to ﬁnally form UDP-GlcNAc (Table II and Fig. 4). Another 4 targets
(GLK1, PSA1, PMI40 and PMM1) are in the GDP-Man biosynthetic
pathway. UDP-GlcNAc and GDP-Man are nucleotide sugar donors
that reside in the cytoplasmic side of the ER membrane, where
GlcNAc and mannose molecules are added in the N-linked glycan.
Increased production of glycosylated protein would therefore also
increase the requirements of these precursors.
Figure 3. The effect of glycosylation on protein production. (A) Protein yields when no N-glycosylation is taken into account (white) and when undergoing humanized N-
glycosylation (grey), relative to protein yield during native N-glycosylation (which would occur in non-glycoengineered strains). Protein yields are given as relative moles. (B)
Humanized protein yields on different carbon sources, relative to the yield on glucose. Units are moles of proteins per Cmol of the substrate. (C) Oxygen requirement of EPO
production for different carbon sources, normalized to the oxygen requirements on glucose (mol/Cmol).
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Two targets are related to the pentose phosphate pathway (GND2
and GNK1). The pentose phosphate pathway can be argued to have
two biological functions: providing pentose sugars for the
biosynthesis of ribonucleotides, which are used in DNA and
RNA, and the regeneration of NADPþ to NADPH, providing
reducing potential for reductive processes in the cell. While an
increased protein production yield would not increase the
ribonucleotide requirements, it is plausible that the NADPH
requirements of the cell increase. The potential of PPP as an
overexpression target for increased protein production has
previously been identiﬁed and validated for hSOD production in
P. pastoris (Nocon et al., 2014).
Another group of targets are related to sulfur metabolism
(Table II). When comparing the amino acid composition of the
whole P. pastoris proteome (Carnicer et al., 2009) with EPO, most of
the amino acids are present in comparable amounts, mostly within
two-fold differences (Table III). Cysteine, however, is present at a
15-fold higher amount in EPO compared to the proteins that make
up P. pastoris biomass, while the cysteine content of P. pastoris is less
than 50% the content in S. cerevisiae (Sohn et al., 2010). As cysteine
is a sulfur containing protein, an increased requirement of cysteine
will demand a similar increase in sulfur. Interestingly, the potential
of the MET genes (Table II) as potential targets is corroborated with
the ﬁndings that genes of methionine pathway are upregulated after
a shift from glycerol to methanol as a carbon source, which induced
the expression of recombinant protein (Sauer et al., 2004).
In addition to EPO, FSEOF was also performed for Alb-Redhill,
which contains less glycosylation sites per amino acid, has a
Table II. Targets predicted by FSEOF for increased production of EPO or Alb-Redhill using FSEOF.
Reaction Gene Abbreviation Reaction
Fold change
Alb-Redhill
Fold change
EPO Group
r550 PAS_chr3_1192 GLK1 ATPþmannose!ADPþmannose 6-P 111 12 GDP-Man
r635 PAS_chr2-1_0093 PSA1 GDPþmannose 1-P$ phosphateþGDP-mannose 21 12 GDP-Man
r992 PAS_chr2-2_0053 PMM1 Mannose 6-P$mannose 1-P 21 12 GDP-Man
r983 PAS_chr3_1115 PMI40 Mannose 6-P$ fructose 6-P 6.2 10 GDP-Man
r526 PAS_chr2-1_0626 GFA1 Fructose 6-Pþ glutamine! glutamateþGlcN 6-P 63 12 UDP-GlcNAc
r390 PAS_chr4_0060 GNA1 Acetyl-CoAþGlcN 6-P$ CoAþGlcNAc 6-P 63 12 UDP-GlcNAc
r636 PAS_chr3_0676 UAP1 UTPþGlcNAc 1-P$ diphosphateþUDP-GlcNAc 63 12 UDP-GlcNAc
r991 PAS_chr1-1_0067 PCM1 GlcNAc 6-P$GlcNAc 1-P 63 12 UDP-GlcNAc
r448 PAS_chr1-4_0417 ALG11 GDP-mannoseþ (GlcNAc)2(Man)3(PP-Dol)!GDPþ (GlcNAc)2(Man) 4
(PP-Dol)
23 12 N-glycan
r452 PAS_c121_0002 ALG2 GDP-mannoseþ (GlcNAc)2(Man)1(PP-Dol)!GDPþ (GlcNAc)2(Man) 2
(PP-Dol)
23 12 N-glycan
r455 PAS_chr2-1_0759 ALG1 GDP-mannoseþ Chitobiosyl-PP-dolichol!GDPþ (GlcNAc)2(Man) 1(PP-
Dol)
23 12 N-glycan
r454 PAS_chr3_0944 ALG13 UDP-GlcNAcþGlcNAc-PP-dolichol!UDPþ Chitobiosyl-PP-dolichol 23 12 N-glycan
r661 PAS_chr2-1_0727 ALG7 UDP-GlcNAcþ P-dolichol!UMPþGlcNAc-PP-dolichol 23 12 N-glycan
r465 PAS_chr1-1_0459 DPM1 GDP-mannoseþ P-dolichol!GDPþ P-dolichol mannose 23 12 N-glycan
r2025 PAS_chr4_0712 ALG3 P-dolichol mannoseþ (GlcNAc)2(Man)4(PP-Dol)! P-
dolicholþ (GlcNAc)2(Man)6(PP-Dol)
23 12 N-glycan
r2026 PAS_chr2-2_0036 ALG9 P-dolichol mannoseþ (GlcNAc)2(Man)6(PP-Dol)! P-
dolicholþ (GlcNAc)2(Man)7(PP-Dol)
23 12 N-glycan
r2027 PAS_chr4_0544 ALG12 P-dolichol mannoseþ (GlcNAc)2(Man)7(PP-Dol) ! P-
dolicholþ (GlcNAc)2(Man)8(PP-Dol)
23 12 N-glycan
r2031 PAS_chr2-1_0549 ALG6 P-dolichol glucosylþ (GlcNAc)2(Man)9(PP-Dol)! P-
dolicholþ (Glc)1(GlcNAc)2(Man)9(PP-Dol)
23 12 N-glycan
r2032 PAS_chr3_0999 ALG8 P-dolichol glucosylþ (Glc)1(GlcNAc)2(Man)9(PP-Dol)! P-
dolicholþ (Glc)2(GlcNAc)2(Man)9(PP-Dol)
23 12 N-glycan
r2033 PAS_chr1-4_0475 ALG10 P-dolichol glucosylþ (Glc)2(GlcNAc)2(Man)9(PP-Dol)! P-
dolicholþ (Glc)3(GlcNAc)2(Man)9(PP-Dol)
23 12 N-glycan
r2029 PAS_chr2-2_0552 ALG5 UDP-glucoseþ P-dolichol!UDPþ P-dolichol glucosyl 23 12 N-glycan
r72 PAS_chr3_0277 GND2 NADPþþ 6-P-gluconate! CO2þNADPHþRibulose 5-P 23 12 PPP
r558 PAS_chr1-4_0669 GNK1 ATPþ gluconic acid!ADPþ 6-P-gluconate 23 12 PPP
r915 PAS_chr2-2_0137 CYS4 SerineþH2S! Cysteine 102 1.7 Sulfur
r567 PAS_chr3_0667 MET14 ATPþ adenylyl sulfate!ADPþ 30-P-adenylyl sulfate 23 1.7 Sulfur
r144 PAS_chr3_0058 ARH1 NADPþþ 2 reduced ferredoxin$NADPHþ 2 oxidized ferredoxin 23 — Sulfur
r598 PAS_chr1-4_0253 MET3 ATPþ sulfate! diphosphateþ adenylyl sulfate 23 1.7 Sulfur
r733 PAS_chr2-1_0547 MET22 adenosine 30 ,50-PP! phosphateþAMP 23 1.7 Sulfur
r281 PAS_chr2-2_0480 TRR1 NADPþþ thioredoxin$NADPHþ thioredoxin-S2 20 1.7 Sulfur
r228 PAS_chr3_0225 SDH1 Succinateþ FAD$ fumarateþ FADH2 13 17 Glyoxylate
r878 PAS_chr1-4_0338 ICL1 Isocitrate! glyoxylateþ succinate 13 17 Glyoxylate
r534 PAS_chr4_0416 AGX1 Glyoxylateþ alanine! pyruvateþ glycine 13 17 Glyoxylate
Abbreviations for gene names were taken from their S. cerevisiae homologs when they have not been deﬁned for P. pastoris. Fold changes indicate the increase that is required
to go from the experimental to the theoretical protein production yield.
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different amino acid composition, and the experimental data used
for the experimental yield was based on growth on glucose
instead of methanol and mannitol (Maccani et al., 2014).
Regardless of these differences, ampliﬁcation targets suggested by
FSEOF were similar for both proteins. While the fold-changes of
the different groups are larger for Alb-Redhill, due to the larger
difference in the experimental and the theoretical yield, they
follow the same trend.
Figure 4. Schematic overview of amplifications targets predicted by FSEOF. Names of potential amplification targets are indicated by their abbreviation, corresponding to
Table II.
Table III. Amino acid composition of Alb-Redhill, EPO, and P. pastoris proteome.
Amino Acid % in Alb-Redhill % in EPO % in proteome Difference Alb-Redhill vs. proteome Difference EPO vs. proteome
Alanine 10 10 10 1.0 1.0
Arginine 4.6 6.7 5.9 0.8 1.1
Asparagine 2.8 3.1 4.7 0.6 0.7
Aspartate 5.9 3.1 4.7 1.3 0.7
Cysteine 5.7 2.6 0.2 32.8 14.8
Glutamate 10 6.7 8.2 1.2 0.8
Glutamine 3.3 3.6 8.2 0.4 0.4
Glycine 2.1 6.2 7.3 0.3 0.9
Histidine 2.6 1.6 1.8 1.4 0.9
Isoleucine 1.5 2.6 4.4 0.3 0.6
Leucine 10 17 7.4 1.4 2.3
Lysine 9.8 4.1 6.7 1.5 0.6
Methionine 1.1 1.0 0.8 1.5 1.4
Phenylalanine 5.7 2.1 3.2 1.8 0.6
Proline 3.9 5.7 4.1 0.9 1.4
Serine 4.6 6.2 6.7 0.7 0.9
Threonine 4.9 5.7 5.9 0.8 1.0
Tryptophan 0.3 2.6 1.4 0.2 1.9
Tyrosine 3.1 2.1 2.3 1.4 0.9
Valine 7.0 6.7 6.2 1.1 1.1
Underlined is the largest difference between recombinant proteins and P. pastoris proteome.
Values for P. pastoris proteome obtained from (Carnicer et al., 2009).
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Conclusion
Here, we generated the ﬁrst functional GEM of P. pastoris,
ihGlycopastoris that includes N-glycosylation and is capable of
simulating humanized glycosylation. Our results demonstrated that
N-glycosylation should be taken into account when one uses GEMs
to study recombinant protein expression in P. pastoris, as failing to
do so, results in production yields that are too high. The genetic
engineering of humanized N-glycosylation lowers the protein yield
further, while the precise effect is dependent on N-glycosylation
level (number of sites/number of amino acids), as the glycosylation
competes for carbons with amino acid biosynthesis.
In ihGlycopastoris, we introduced N-glycosylation for recombi-
nant protein production. It should be noted that also native
P. pastoris proteins undergo N-glycosylation, however, this was
not taken into account. Effort has been made to model
N-glycosylation of the proteome of S. cerevisiae (Feizi, Marras,
Nielsen, manuscript in preparation), however, instrumental for
this is the availability of genome-wide measurements of
N-glycosylation. This extension is currently out of reach for
P. pastoris as this data is unavailable. The absence of
N-glycosylation of native P. pastoris in ihGlycopastoris also
inﬂuences the FSEOF analysis, as the absence of N-glycans in
P. pastoris biomass puts more weight on the presence of N-glycans
in the recombinant protein. While this model is an improvement
over previous genome-scale models of P. pastoris that do not take
N-glycosylation into account, there is potential to further improve
the model by describing processes involved in (recombinant)
protein production that are currently not covered by our model.
Processes such as protein folding, but also the remainder of the
secretory pathway have been identiﬁed as having a severe effect
on protein yields (Hohenblum et al., 2004). While inefﬁciencies of
protein expression, such as aggregation, mis-targeting, and
degradation are affecting protein yield, also the nature of the
protein, e.g., its hydrophobicity, arrangement and composition of
amino acids, affect protein yield. The absence of these processes
in the current model are likely responsible for the discrepancy
between the experimental and model predicted protein yields,
indicating that future iterations of this model could further
improve its application. Additionally, the current model does not
take the micro- and macroheterogeneity of N-glycosylation into
account, especially for the N-glycosylation of P. pastoris’ native
proteome. A more detailed incorporation would beneﬁt from the
challenging experimental measurements of the N-glycosylation of
P. pastoris native protein. For S. cerevisiae, for which there is more
information available, the protein secretory machinery has been
modelled in more detail (Feizi et al., 2013). Nonetheless,
ihGlycopastoris is an important step forward to gain a more
accurate description of protein production in microbes.
References
Agren R, Liu L, Shoaie S, Vongsangnak W, Nookaew I, Nielsen J. 2013. The RAVEN
toolbox and its use for generating a genome-scale metabolic model for
Penicillium chrysogenum. PLoS Comput Biol 9:e1002980.
Barrigon JM, Valero F, Montesinos JL. 2015. A macrokinetic model-based
comparative meta-analysis of recombinant protein production by Pichia
pastoris under AOX1 promoter. Biotechnol Bioeng 112:1132–1145.
Brennan SO, Myles T, Peach RJ, Donaldson D, George PM. 1990. Albumin Redhill (-1
Arg, 320 Ala--Thr): A glycoprotein variant of human serum albumin whose
precursor has an aberrant signal peptidase cleavage site. Proc Natl Acad Sci
87:26–30.
Bretthauer RK. 2003. Genetic engineering of Pichia pastoris to humanize N-
glycosylation of proteins. Trends Biotechnol 21:459–462.
SCalik P, Inankur B, Soyaslan ES , Sahin M, TaSspinar H, ASc ik E, Bayraktar E. 2010.
Fermentation and oxygen transfer characteristics in recombinant human
growth hormone production by Pichia pastoris in sorbitol batch and methanol
fed-batch operation. J Chem Technol Biotechnol 85:226–233.
Carnicer M, Baumann K, T€oplitz I, Sanchez-Ferrando F, Mattanovich D, Ferrer P,
Albiol J. 2009. Macromolecular and elemental composition analysis and
extracellular metabolite balances of Pichia pastoris growing at different oxygen
levels. Microb Cell Fact 8:65.
Caspeta L, Shoaie S, Agren R, Nookaew I, Nielsen J. 2012. Genome-scale metabolic
reconstructions of Pichia stipitis and Pichia pastoris and in silico evaluation of
their potentials. BMC Syst Biol 6:24.
Cereghino J. 2000. Heterologous protein expression in the methylotrophic yeast
Pichia pastoris. FEMS Microbiol Rev 24:45–66.
Chen W, Smeekens JM, Wu R. 2014. Comprehensive analysis of protein N-
glycosylation sites by combining chemical deglycosylation with LC-MS.
J Proteome Res 13:1466–1473.
Chiba Y, Akeboshi H. 2009. Glycan engineering and production of “humanized”
glycoprotein in yeast cells. Biol Pharm Bull 32:786–795.
Choi HS, Lee SY, Kim TY,Woo HM. 2010. In silico identiﬁcation of gene ampliﬁcation
targets for improvement of lycopene production. Appl Environ Microbiol
76:3097–3105.
Chung BK, Selvarasu S, Andrea C, Ryu J, Lee H, Ahn J, Lee H, Lee DY. 2010. Genome-
scale metabolic reconstruction and in silico analysis of methylotrophic yeast
Pichia pastoris for strain improvement. Microb Cell Fact 9:50.
Cregg JM, Cereghino JL, Shi J, Higgins DR. 2000. Recombinant protein expression in
Pichia pastoris. Mol Biotechnol 16:23–52.
Delic M, Valli M, Graf AB, Pfeffer M, Mattanovich D, Gasser B. 2013. The secretory
pathway: Exploring yeast diversity. FEMS Microbiol Rev 37:872–914.
Dragosits M, Stadlmann J, Albiol J, Baumann K, Maurer M, Gasser B, Sauer M,
Altmann F, Ferrer P, Mattanovich D. 2009. The effect of temperature on the
proteome of recombinant Pichia pastoris. J Proteome Res 8:1380–1392.
Eskitoros MS , Ata €O, SCalık P. 2014. Metabolic reaction network of Pichia pastoris with
glycosylation reactions: Flux analysis for erythropoietin production. J Chem
Technol Biotechnol 89:1675–1685.
Eskitoros MS , SCalık P. 2014. Co-substrate mannitol feeding strategy design in semi-
batch production of recombinant human erythropoietin production by Pichia
pastoris. J Chem Technol Biotechnol 89:644–651.
Feizi A, €Osterlund T, Petranovic D, Bordel S, Nielsen J. 2013. Genome-scale modeling
of the protein secretory machinery in yeast. PLoS ONE 8:e63284.
Gach JS, Maurer M, Hahn R, Gasser B, Mattanovich D, Katinger H, Kunert R. 2007.
High level expression of a promising anti-idiotypic antibody fragment vaccine
against HIV-1 in Pichia pastoris. J Biotechnol 128:735–746.
Gemmill TR, Trimble RB. 1999. Overview of N- and O-linked oligosaccharide
structures found in various yeast species. Biochim Biophys Acta 1426:227–237.
Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, Bobrowicz P,
Stadheim TA, Li H, Choi BK., Hopkins D, Wischnewski H, Roser J, Mitchell T,
Strawbridge RR, Hoopes J, Wildt S, Gerngross TU. 2006. Humanization of
yeast to produce complex terminally sialylated glycoproteins. Science
313:1441–1443.
Hamilton SR, Gerngross TU. 2007. Glycosylation engineering in yeast: The advent of
fully humanized yeast. Curr Opin Biotechnol 18:387–392.
Helenius A, Aebi M. 2001. Intracellular functions of N-linked glycans. Science
291:2364–2369.
Hohenblum H, Gasser B, Maurer M, Borth N, Mattanovich D. 2004. Effects of gene
dosage, promoters, and substrates on unfolded protein stress of recombi-
nantPichia pastoris. Biotechnol Bioeng 85:367–375.
Jorda J, de Jesus SS, Peltier S, Ferrer P, Albiol J. 2014. Metabolic ﬂux analysis of
recombinant Pichia pastoris growing on different glycerol/methanol mixtures
by iterative ﬁtting of NMR-derived 13C-labelling data fromproteinogenic amino
acids. N Biotechnol 31:120–132.
Jungo C, Rerat C, Marison IW, von Stockar U. 2006. Quantitative characterization of
the regulation of the synthesis of alcohol oxidase and of the expression of
968 Biotechnology and Bioengineering, Vol. 113, No. 5, May, 2016
recombinant avidin in a Pichia pastoris Mutþ strain. Enzyme Microb Technol
39:936–944.
Jungo C, Marison I, von Stockar U. 2007a. Mixed feeds of glycerol and methanol can
improve the performance of Pichia pastoris cultures: A quantitative study based
on concentration gradients in transient continuous cultures. J Biotechnol
128:824–837.
Jungo C, Schenk J, Pasquier M, Marison IW, von Stockar U. 2007b. A quantitative
analysis of the beneﬁts of mixed feeds of sorbitol and methanol for the
production of recombinant avidin with Pichia pastoris. J Biotechnol
131:57–66.
Jungo C, Urfer J, Zocchi A, Marison I, von Stockar U. 2007c. Optimisation of culture
conditionswith respect to biotin requirement for the production of recombinant
avidin in Pichia pastoris. J Biotechnol 127:703–715.
Karaoglu D, Kelleher DJ, Gilmore R. 1997. The highly conserved Stt3 protein is a
subunit of the yeast oligosaccharyltransferase and forms a subcomplex with
Ost3p and Ost4p. J Biol Chem 272:32513–32520.
Keating SM, Bornstein BJ, Finney A, Hucka M. 2006. SBMLToolbox: An SBML
toolbox for MATLAB users. Bioinformatics 22:1275–1277.
Kerkhoven EJ, Lahtvee PJ, Nielsen J. 2015. Applications of computational modeling in
metabolic engineering of yeast. FEMS Yeast Res 15:1–13.
KimB, KimWJ, KimDI, Lee SY. 2014. Applications of genome-scalemetabolic network
model in metabolic engineering. J Ind Microbiol Biotechnol 42:339–348.
Kobayashi K, Nakamura N, Sumi A, Ohmura T, Yokoyama K. 1998. The development
of recombinant human serum albumin. Ther Apher 2:257–262.
Maccani A, Landes N, Stadlmayr G, Maresch D, Leitner C, Maurer M, Gasser B, Ernst
W, Kunert R, Mattanovich D. 2014. Pichia pastoris secretes recombinant
proteins less efﬁciently than Chinese hamster ovary cells but allows higher
space-time yields for less complex proteins. Biotechnol J 9:526–537.
Marx H, Mecklenbr€auker A, Gasser B, Sauer M, Mattanovich D. 2009. Directed gene
copy number ampliﬁcation in Pichia pastoris by vector integration into the
ribosomal DNA locus. FEMS Yeast Res 9:1260–1270.
Nocon J, Steiger MG, Pfeffer M, Sohn SB, Kim TY, Maurer M, Rußmayer H, Pﬂ€ugl S,
Ask M, Haberhauer-Troyer C, Ortmayr K, Hann S, Koellensperger G, Gasser B,
Lee SY, Mattanovich D. 2014. Model based engineering of Pichia pastoris central
metabolism enhances recombinant protein production. Metab Eng 24:129–138.
Puxbaum V, Mattanovich D, Gasser B. 2015. Quo vadis? The challenges of
recombinant protein folding and secretion in Pichia pastoris. Appl Microbiol
Biotechnol 99:2925–2938.
Samuelson J, Banerjee S, Magnelli P, Cui J, Kelleher DJ, Gilmore R, Robbins PW. 2005.
The diversity of dolichol-linked precursors to Asn-linked glycans likely results
from secondary loss of sets of glycosyltransferases. Proc Natl Acad Sci USA
102:1548–1553.
Sauer M, Branduardi P, Gasser B, Valli M, Maurer M, Porro D, Mattanovich D.
2004. Differential gene expression in recombinant Pichia pastoris
analysed by heterologous DNA microarray hybridisation. Microb Cell
Fact 3:17.
Sohn SB, Graf AB, Kim TY, Gasser B, Maurer M, Ferrer P, Mattanovich D, Lee SY.
2010. Genome-scale metabolic model of methylotrophic yeast Pichia pastoris
and its use for in silico analysis of heterologous protein production. Biotechnol J
5:705–715.
Sola A, Maaheimo H, Yl€onen K, Ferrer P, Szyperski T. 2004. Amino acid biosynthesis
and metabolic ﬂux proﬁling of Pichia pastoris. Eur J Biochem 271:2462–
2470.
Sola A, Jouhten P, Maaheimo H, Sanchez-Ferrando F, Szyperski T, Ferrer P. 2007.
Metabolic ﬂux proﬁling of Pichia pastoris grown on glycerol/methanol
mixtures in chemostat cultures at low and high dilution rates. Microbiology
153:281–290.
Tortajada Serra M. 2012. Process development for the obtention and use of
recombinant glycosidases: Expression, modelling, and immobilisation;
Universitat Politecnica de Valencia.
Trimble RB, Atkinson PH, Tschopp JF, Townsend RR, Maley F. 1991. Structure of
oligosaccharides on Saccharomyces SUC2 invertase secreted by the methyl-
otrophic yeast Pichia pastoris. J Biol Chem 266:22807–22817.
Zhan H, Liu B, Reid SW, Aoki KH, Li C, Syed RS, Karkaria C, Koe G, Sitney K,
Hayenga K, Mistry F, Savel L, Dreyer M, Katz BA, Schreurs J, Matthews DJ,
Cheetham JC, Egrie J, Giebel LB, Stroud RM. 1999. Engineering a soluble
extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate
microheterogeneity, and its complex with erythropoietin. Protein Eng
12:505–513.
Zhang W, Liu CP, Inan M, Meagher MM. 2004. Optimization of cell density and
dilution rate in Pichia pastoris continuous fermentations for production of
recombinant proteins. J Ind Microbiol Biotechnol 31:330–334.
Supporting Information
Additional supporting information may be found in the online
version of this article at the publisher’s web-site.
Irani et al.: N-Glycosylation in Pichia pastoris 969
